BioAxone BioSciences Inc is a Boston-based biopharmaceutical company dedicated to developing innovative drug candidates for individuals suffering from neurotrauma and neurovascular disorders. Their mission is to reduce disability and improve the lives of patients through the creation and advancement of effective treatments. With a focus on spinal cord injury and cerebral vascular disorders, BioAxone is actively involved in the development of drug candidates targeting axon regeneration and blood-brain barrier dysfunction.
Through their commitment to research and development, BioAxone has achieved significant milestones, including the licensing of their ROCK2 inhibitor to Neurelis for the treatment of cerebral cavernous malformation (CCM) and other related conditions. Additionally, they have a Phase 3 Rho inhibitor and a preclinical drug targeting spinal cord injury available for licensing, demonstrating their dedication to advancing therapeutic options for patients in need.
Generated from the website